{"id":48598,"date":"2014-12-11T10:42:10","date_gmt":"2014-12-11T15:42:10","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/chinese-university-of-hong-kong-oncologist-in-cancer-breakthrough\/"},"modified":"2014-12-11T10:42:10","modified_gmt":"2014-12-11T15:42:10","slug":"chinese-university-of-hong-kong-oncologist-in-cancer-breakthrough","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/gene-medicine\/chinese-university-of-hong-kong-oncologist-in-cancer-breakthrough\/","title":{"rendered":"Chinese University of Hong Kong oncologist in cancer &#39;breakthrough&#39;"},"content":{"rendered":"<p><p>    Andrea Deng  <\/p>\n<p>    China Daily  <\/p>\n<p>    Publication Date : 11-12-2014  <\/p>\n<\/p>\n<p>    Targeted therapy was proved effective against a critical    mutated gene found in some lung cancer patients. The milestone    in lung cancer treatment was achieved by an oncologist at    Chinese University of Hong Kong (CUHK).  <\/p>\n<p>    Molecular targeted treatment, using a medicine called    Crizotinib to attack mutated gene EML4-ALK, proved to produce    more dramatic effect than standard chemotherapy, said CUHK    clinical oncologist Tony Mok Shu-kam on Wednesday (Dec 10).  <\/p>\n<p>    CUHK oncologists have recommended EML4-ALK test for every lung    cancer patient, so that they may choose targeted therapy as a    more effective treatment, in the event of testing positive.  <\/p>\n<p>    Mok worked with Australian expert Benjamin Solomon between 2011    and 2013 to study the effect on 343 stage-four lung cancer    patients in 27 countries and regions. Patients were equally    divided into two groups, one undergoing standard chemotherapy    and the other taking Crizotinib. The study showed that those    who received targeted therapy usually lived longer than those    subjected to standard chemotherapy.  <\/p>\n<p>    While a large number of patients of both groups managed to    survive for five months, only two out of 171 patients exposed    to standard chemotherapy survived 20 months, while only 19 out    of the 172 people undergoing targeted therapy did so.  <\/p>\n<p>    Some of the patients who received Crizotinib are still alive,    after more than two years.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read more from the original source:<br \/>\n<a target=\"_blank\" href=\"http:\/\/asianewsnetwork.feedsportal.com\/c\/33359\/f\/566601\/s\/4152eb1d\/sc\/14\/l\/0L0Sasianewsnet0Bnet0Cnews0E6890A40Bhtml\/story01.htm\/RK=0\/RS=aqYXfzYVWd4pjRLNWjeCTEOP4gM-\" title=\"Chinese University of Hong Kong oncologist in cancer &#39;breakthrough&#39;\">Chinese University of Hong Kong oncologist in cancer &#39;breakthrough&#39;<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Andrea Deng China Daily Publication Date : 11-12-2014 Targeted therapy was proved effective against a critical mutated gene found in some lung cancer patients. The milestone in lung cancer treatment was achieved by an oncologist at Chinese University of Hong Kong (CUHK). Molecular targeted treatment, using a medicine called Crizotinib to attack mutated gene EML4-ALK, proved to produce more dramatic effect than standard chemotherapy, said CUHK clinical oncologist Tony Mok Shu-kam on Wednesday (Dec 10) <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/gene-medicine\/chinese-university-of-hong-kong-oncologist-in-cancer-breakthrough\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[21],"tags":[],"class_list":["post-48598","post","type-post","status-publish","format-standard","hentry","category-gene-medicine"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/48598"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=48598"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/48598\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=48598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=48598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=48598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}